程序性死亡1抗体/PD-1 Antibody |
|
|
产品名称 ： 程序性死亡1抗体/PD-1 Antibody
产品类别 ： IVD诊断抗体原料
品 牌 ： GenomeMe
货 号 ： IHC001
规 格 ： 0.1ml/1ml
|
|
详细信息 |
|
|
纯化方式 ：
缓 冲 液 ：
应用说明 ：
形 态 ：
产品说明 ：
背景描述Description：
程序性死亡1(ProgrammedDeath 1，PD-1)是CD28/CTLA-4家族的一员，表达于活化的T细胞、B细胞和巨噬细胞表面。新的研究表明PD-1/PD-L1信号通路可能与抗肿瘤免疫有关，因为PD-L1可诱导活化的T细胞凋亡或抑制细胞毒性T细胞的活性。与CD10和Bcl-6相比，PD-1由较少的B细胞表达，因此被认为是诊断血管免疫母细胞性T细胞淋巴瘤的更特异、更有用的标记物。针对PD-1受体的治疗已经在包括非小细胞肺癌、黑色素瘤和肾细胞癌在内的各种癌症患者中显示出显著的临床疗效。
Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators, expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumor immunity, as PD-L1 has been shown to induce apoptosis of activated T cells or inhibit activity of cytotoxic T cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T-cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non–small-cell lung cancer, melanoma, and renal-cell cancer.
Specifications：
Clone IHC001
Source Mouse Monoclonal
Positive Control Tonsil, Lymph Node
Dilution Range 1:50-1:200
参考文献References：
Dorfman DM, et al. Am J Surg Pathol. 2006; 30:802-10.
Hamanishi J, et al. Proc Natl Acad Sci USA. 2007; 104:3360-5.
Kobayashi M, et al. J Rheumatol. 2005; 32:2156-63.
Konishi J, et al. Clin Cancer Res. 2004; 10:5094-100.
Mataki N, et al. Am J Gastroenterol. 2007; 102:302-12.
Kim JW, et al. Oncology (Williston Park). 2014; 28:15-28.
Tumeh PC, et al. Nature. 2014; 515:568-71.
D’Incecco A, et al. Br J Cancer. 2015; 112:95-102.
Tykodi SS. Onco Targets Ther. 2014; 7:1349-59.
|
|
| {返回} | |
| |||||||||||
